NUVATION BIO’s Execs Pump Up Shares as Fast‑Track Drug Sparks Insider Buying Frenzy
See why NUVATION BIO’s insider buys signal bullish confidence as safusidenib races toward Phase 3 approval and a potential market rally.
3 minutes to read
NUVATION BIO INC